| Q61698756 | Q61698756 |
| Q42831857 | "Immunotherapy of cancer: present status and future promise": Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd-25th September 2013. |
| Q28553703 | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one |
| Q112570545 | A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| Q30040092 | Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor Reactivity |
| Q38665896 | Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling. |
| Q57177466 | Acquired resistance to cancer immunotherapy |
| Q36444798 | Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients |
| Q59319962 | Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma |
| Q90326770 | Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study |
| Q125391466 | Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types |
| Q27686983 | Advances in targeting signal transduction pathways |
| Q42403183 | Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes |
| Q34510721 | Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. |
| Q34756907 | Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs |
| Q89984072 | Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 |
| Q42417533 | BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer |
| Q41845397 | Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets |
| Q37863500 | Breast cancer: Molecular basis and therapeutic strategies (Review). |
| Q35546276 | Broadening the repertoire of melanoma-associated T-cell epitopes. |
| Q41662222 | CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. |
| Q90009975 | CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer |
| Q52727736 | Cancer immunotherapy in patients with brain metastases. |
| Q38978399 | Cancer immunotherapy in patients with preexisting autoimmune disorders |
| Q104560240 | Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer |
| Q50554742 | Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. |
| Q41915301 | Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model |
| Q125391463 | Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy |
| Q64103702 | Collagen density regulates the activity of tumor-infiltrating T cells |
| Q39319803 | Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. |
| Q39234940 | Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy |
| Q59794424 | Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma |
| Q92488873 | Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer |
| Q34179539 | Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells. |
| Q125391402 | Data from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391425 | Data from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q55342245 | Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. |
| Q125391480 | Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses - implications for the management of irAEs |
| Q90696324 | Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs |
| Q60634943 | Dissection of T-cell Antigen Specificity in Human Melanoma |
| Q37192602 | Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs |
| Q42952683 | Effector CD4 and CD8 T cells and their role in the tumor microenvironment |
| Q46577295 | Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma |
| Q60981645 | Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat |
| Q46605939 | Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. |
| Q43228801 | Eleventh international conference on progress in vaccination against cancer (PIVAC-11), 10-13 October 2011, Copenhagen, Denmark |
| Q92033828 | Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells |
| Q37192616 | Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy |
| Q52733766 | Frequent adaptive immune responses against arginase-1. |
| Q50973652 | Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. |
| Q92784716 | Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 |
| Q90949076 | HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice |
| Q61698794 | HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients |
| Q112572342 | Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy |
| Q39602151 | In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. |
| Q46675288 | In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. |
| Q59090802 | In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models |
| Q39746181 | Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. |
| Q33688931 | Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. |
| Q91601021 | Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer |
| Q40603434 | Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. |
| Q38394457 | Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. |
| Q90079491 | Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression |
| Q112722866 | Loss of Ambra1 promotes melanoma growth and invasion |
| Q91563227 | MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells |
| Q39271021 | Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion |
| Q26864749 | More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers |
| Q47157659 | Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma |
| Q28730430 | Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase |
| Q26781931 | New developments in the management of advanced melanoma - role of pembrolizumab |
| Q37760237 | New perspectives in HCV therapy: entry inhibitors. |
| Q39984965 | Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. |
| Q40146544 | PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer |
| Q40994145 | PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. |
| Q64097880 | Peptide Super-Agonist Enhances T-Cell Responses to Melanoma |
| Q52730243 | Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations. |
| Q112709850 | Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma |
| Q125391461 | Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R) |
| Q60981620 | Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients |
| Q45906790 | Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma. |
| Q24606795 | Potential use of rapamycin in HIV infection |
| Q61698755 | Principles of adoptive T cell therapy in cancer |
| Q102072861 | Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma |
| Q125391476 | Rapid Identification of the Tumor-Specific Reactive TIL Repertoire Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens |
| Q91384611 | Rare cause of spontaneous haemothorax: mediastinal and distant lymph node metastases from uveal melanoma |
| Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
| Q90775726 | Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma |
| Q92277604 | Real-world evidence to guide healthcare policies in oncology |
| Q38550289 | Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. |
| Q46194861 | Role of signal transduction and microRNAs on the immunogenicity of melanoma cells |
| Q34966603 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q59318074 | S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes |
| Q53550817 | Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. |
| Q43709498 | Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents |
| Q125391403 | Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391404 | Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391426 | Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391427 | Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391407 | Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391410 | Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391429 | Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391434 | Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391415 | Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391416 | Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391437 | Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391439 | Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391417 | Supplementary Material 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391419 | Supplementary Material 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391440 | Supplementary Material 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q125391443 | Supplementary Material 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q55710347 | T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients. |
| Q52567363 | T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression. |
| Q50187924 | T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. |
| Q34677333 | Targeting of cancer neoantigens with donor-derived T cell receptor repertoires |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q92669545 | Tertiary lymphoid structures improve immunotherapy and survival in melanoma |
| Q37192611 | The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy |
| Q40437125 | The controversial role of TNF in melanoma |
| Q101466900 | The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro |
| Q50545414 | The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. |
| Q38881585 | The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. |
| Q39850762 | The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis |
| Q90865997 | The real-world impact of modern treatments on the survival of patients with metastatic melanoma |
| Q92686581 | The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous |
| Q39313996 | Therapeutic potential of nitric oxide-modified drugs in colon cancer cells |
| Q125391471 | Transcriptomic signatures of tumors undergoing T cell attack |
| Q45922822 | Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. |
| Q37320131 | Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. |
| Q116030366 | Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma |
| Q92378491 | Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy |
| Q114871652 | Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions |
| Q38636573 | Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. |
| Q91341197 | Tumour-reactive T cell subsets in the microenvironment of ovarian cancer |
| Q125391422 | Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma |
| Q39337196 | Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells |
| Q60981640 | Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis |